5003 – Anti-Gangliosid Dot

Highlights

• Detection of IgG and/or IgM antibodies against gangliosides
• Designed as an aid in diagnosing peripheral neurological disorders
• Quality assured handling in routine laboratories
• Ready-to-use test strips with multiple ganglioside antigens (GM1, GM2, GM3, GM4, GD1a, GD1b, GD2, GD3, GT1a, GT1b, GQ1b, Sulfatide)
• Colorimetric detection via horseradish peroxidase and TMB substrate
• Quantitative assessment with lot-specific interpretation card
• CE marked
• Automatable

Intended Use

The Anti-Gangliosid Dot is a qualitative line immunoassay for the determination of IgG or IgM antibodies against gangliosides in human serum. The Anti-Gangliosid Dot is intended as an aid in the diagnosis of peripheral neurological disorders in conjunction with other clinical and laboratory findings. The immunoassay is designed for manual professional in vitro diagnostic use.

Diagnostic Relevance

Clinical symptoms associated with inflammatory neuropathies of the peripheral nervous system range from mild signs like slight weariness, inexplicable indisposition to complicated cases such as functional deficiency like respiratory paralysis, cardiac arrest and neuromuscular disorders. Gangliosides, acid glycolipids containing a lipid (ceramide), oligosaccharide and sialic acid, are major components of cell membranes and found especially in the central and peripheral nervous system. Autoantibodies to gangliosides are detected in patients suffering from disorders of the peripheral nervous system.

Infection with Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumoniae or Haemophilus influenzae is a risk factor for inflammatory neuropathies: Antibodies to ganglioside structures of these microorganisms may cross-react with gangliosides of the myelin sheath or neurofibre, leading to activation of inflammation processes with subsequent demyelination.

Publications

• Kleiser et al., (2024) Anti-Sulfatide Antibodies in Neurological Disorders: Should We Test?
• Giesche et al., (2024) Antiganglioside Antibody Frequency in Routine Clinical Care Settings
• Gastaldi et al., (2020) Antibody Diagnostics in Neuroimmunology: Experience from the 2018 Italian Neuroimmunology Association EQA Program
• Klehmet et al., (2018) Analysis of Anti-ganglioside Antibodies Using a Line Immunoassay in Patients with CIDP
• Franciotta et al., (2018) Anti-ganglioside Antibodies: Experience from the Italian Association of Neuroimmunology EQA Scheme
• Caudie et al., (2013) Comparison of Commercial Tests for Detecting Multiple Anti-Ganglioside Autoantibodies in Patients with Well-Characterized Immune-Mediated Peripheral Neuropathies